The Bulletin
The Times


.

Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial

  • Written by PR Newswire
Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial

SYDNEY, Nov. 7, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that 50 patients have now been imaged with 64Cu-SAR-Bombesin in its United...

hacklink zlibraryzlibraryz-libraryvippark kayıtPadişahbetjustin tvmatbet girişPadişahbettaraftarium24Sahabetjojobetjojobetjojobetviljo kasinot kirjautuminenGalabetzimpler kasinotGalabet1xbetjojobetcasibomcasibomjojobettaraftarium24taraftariumholiganbethacklink panel